Shin Dong Ho, Alonso Marta M, Gomez-Manzano Candelaria, Fueyo Juan
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Navarra Institute for Health Research (IdISNA), Pamplona, Spain.
Curr Neurol Neurosci Rep. 2025 Jun 14;25(1):41. doi: 10.1007/s11910-025-01428-4.
Virotherapy has emerged as a promising approach to cancer treatment. Over the past two decades, early-phase clinical trials have demonstrated the safety and promising efficacy of virotherapy in subsets of cancer patients. However, a significant knowledge gap needs to be filled to propel the field further and achieve substantial anti-cancer benefits for more than the current 10-20% of treated patients. This article reviews the most relevant current challenges in cancer virotherapy.
Recent clinical observations suggest that patients who respond to virotherapy experience a shift in their immune response from an initial or concomitant response against the virus toward the tumor. Strategies aimed at facilitating the temporary escape of the virus from the immune response and ultimately redirecting the immune response from the virus to the tumor may propel the development of cancer viroimmunotherapy as a potent and versatile approach to cancer treatment. Here, we examine this issue and other current challenges in cancer virotherapy.
病毒疗法已成为一种有前景的癌症治疗方法。在过去二十年中,早期临床试验已证明病毒疗法在部分癌症患者中的安全性和有前景的疗效。然而,需要填补一个重大的知识空白,以进一步推动该领域发展,并为超过目前10%-20%的接受治疗患者带来实质性的抗癌益处。本文综述了癌症病毒疗法当前最相关的挑战。
最近的临床观察表明,对病毒疗法有反应的患者的免疫反应会从最初或同时针对病毒的反应转向针对肿瘤的反应。旨在促进病毒暂时逃避免疫反应并最终将免疫反应从病毒重定向至肿瘤的策略,可能会推动癌症病毒免疫疗法作为一种有效且通用的癌症治疗方法的发展。在此,我们探讨这个问题以及癌症病毒疗法当前的其他挑战。